Abou-Alfa GK et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(6):796-807. Abstract
Abou-Alfa GK et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol 2020;21(5):671-84. Abstract
Berchuck JE et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol 2022;33(12):1269-83. Abstract
Engstrom LD et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov 2023;13(11):2412-31. Abstract
Goyal L et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388(3):228-39. Abstract
Goyal L et al. Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N Engl J Med 2021;384(11):1054-64. Abstract
Goyal L et al. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev 2021;95:102170. Abstract
Harding JJ et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study. Lancet Oncol 2023;24(7):772-82. Abstract
Hatia RI et al. Independent of primary sclerosing cholangitis and cirrhosis, early adulthood obesity is associated with cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 2023;32(10):1338-47. Abstract
Hollebecque A et al. Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. ESMO 2022;Abstract LBA12.
Javle MM et al. Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis. Gastrointestinal Cancers Symposium 2023;Abstract 539.
Javle M et al. Temporal changes in cholangiocarcinoma incidence and mortality in the united states from 2001 to 2017. Oncologist 2022;27(10):874-83. Abstract
Javle M et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22(9):1290-300. Abstract
Javle M et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018;36(3):276-82. Abstract
Javle M et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer 2016;122(24):3838-47. Abstract
Kelley RK et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10391):1853-65. Abstract
Kendre G et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol 2023;78(3):614-26. Abstract
Lamarca A et al. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J Hepatol 2020;73(1):170-85. Abstract
Liu A et al. Genetics and epigenetics of glioblastoma: Applications and overall incidence of IDH1 mutation. Front Oncol 2016:6:16. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. ASCO 2023;Abstract LBA3000.
Meric-Bernstam F et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. ESMO 2023;Abstract LBA34.
Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. Gastrointestinal Cancers Symposium 2021;Abstract 299.
Nakamura Y et al. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. ASCO 2023;Abstract 4007.
Oh D-Y et al. CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study. Gastrointestinal Cancers Symposium 2023;Abstract 540.
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1(8). Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
Subbiah V et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234-43. Abstract
Valderrama A et al. Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population. Gastrointestinal Cancers Symposium 2022;Abstract 398.
Valle J et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362(14):1273-81. Abstract
Vogel A et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202. ESMO GI 2022;Abstract O-2.
Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7(11):1669-77. Abstract